AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Saving lives, Reducing costs

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

What problems do we solve?According to WHO, 14 million cancer patients are treated annually with conventional chemotherapy.

ProblemNearly 50% of these chemotherapy patients do not get much benefit from the treatments.

They experience all the anguishes of chemotherapy but their tumors progress and their condition persists.

Physicians then have to switch to a different regimen of chemotherapy, if it is not too late!

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

AccuDava solution

We have developed an unprecedented molecular process to improve efficacy of personalizing cancer chemotherapy.

Our test enables physicians to avoid ineffective drugs and select suitable treatments, based on a patient’s tumor molecular characteristics – before treatment begins.

All this from a 60-minute test on a tumor sample.

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

AccuDava’s technology is based on the identification of two “Cell-Surface Glycan Biomarkers”

Specificity of AccuDava BiomarkersIt is on the cell-surface not within the cell.It is a carbohydrate motif, not genomic or protein.

- Glycans are dynamic molecules involved in cell-signaling, and on the front line of cell communication and defense.

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Chemo-sensitivecancer cell

(10X more biomarker on chemo-susceptible than

chemo-resistant)

Chemo-Resistantcancer cell

Nucleus

Glycan biomarker

Nucleus

Presentation of the cell-surface glycan biomarker over-expression on cancer cells

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Detecting Method of the glycan biomarker

tumor

tumor

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Histochemical staining of retrospective human ovarian cancer tumor sections

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Science teamNahid Razi, Ph.D., Founder and Principle Investigator

Afshin Bahador, M.D., Director of Clinical ResearchOBGYN and Surgical oncologist South Coast Gynecologic Oncology, Inc.

Nissi Varki, M.D., Professor of Pathology at UCSD,Director of the UCSD histology and pathology laboratory

Nathalie Scholler, M.D., Ph.D., Professor of OBGYN and Oncology at University of Pennsylvania,

Specialist in ovarian cancer biomarkers- MesoMarkTM

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Management TeamNahid Razi - President

Hedi Jafari, MBA - CFOFinancial manager at UCSD

Afshin Bahador, MD - Managing partner

David Larson - Business advisorCFO/COO True Diagnostics

Scientific AdvisorProfessor Ulf Lindahl- Senior member of the Swedish Royal Academy of Science, member of the Nobel Prize committee

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Achievements10 years of investigations identified two “glycan biomarkers” for drug responseDeveloped assays for detecting those biomarkersVerified the assays' reliability, reproducibility and specificity on human cancer specimensValidated the clinical correlation of the biomarkers with drug efficacy, on retrospective ovarian cancer tumor sectionsApplied for 2 patents, received 1, the other in process

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

Intellectual Property

Two Patents filed by Knobbe-MartensOne issued patent (2009)One pending (recently filed)Filed under the name of Nahid Razi, Ph.D.

AccuDava, Inc.AccuDava, Inc.Personalized Molecular Cancer Diagnostics

2 milestones to MarketMilestone #1 - Preclinical Verification100-200 ovarian cancer patients (sites identified)12-18 monthsCreate protocols for Clinical trial

Milestone #2 - Clinical Studies + PMA (FDA Clearance)FDA required number of ovarian cancer patients18-24 months (est.)Produce data to support PMA for FDA approval